HRP20210342T8 - Glycopeptide compositions - Google Patents

Glycopeptide compositions

Info

Publication number
HRP20210342T8
HRP20210342T8 HRP20210342TT HRP20210342T HRP20210342T8 HR P20210342 T8 HRP20210342 T8 HR P20210342T8 HR P20210342T T HRP20210342T T HR P20210342TT HR P20210342 T HRP20210342 T HR P20210342T HR P20210342 T8 HRP20210342 T8 HR P20210342T8
Authority
HR
Croatia
Prior art keywords
glycopeptide compositions
glycopeptide
compositions
Prior art date
Application number
HRP20210342TT
Other languages
Croatian (hr)
Inventor
Ivona JASPRICA
Sabina KESER
Katarina PINDRIC
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210342(T8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of HRP20210342T1 publication Critical patent/HRP20210342T1/en
Publication of HRP20210342T8 publication Critical patent/HRP20210342T8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HRP20210342TT 2014-11-06 2021-03-01 Glycopeptide compositions HRP20210342T8 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462076400P 2014-11-06 2014-11-06
US201562168749P 2015-05-30 2015-05-30
PCT/EP2015/075918 WO2016071495A1 (en) 2014-11-06 2015-11-06 Glycopeptide compositions
EP19174849.0A EP3542812B1 (en) 2014-11-06 2015-11-06 Glycopeptide compositions

Publications (2)

Publication Number Publication Date
HRP20210342T1 HRP20210342T1 (en) 2021-04-30
HRP20210342T8 true HRP20210342T8 (en) 2022-01-21

Family

ID=54478023

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20200101TT HRP20200101T1 (en) 2014-11-06 2020-01-21 Glycopeptide compositions
HRP20210342TT HRP20210342T8 (en) 2014-11-06 2021-03-01 Glycopeptide compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20200101TT HRP20200101T1 (en) 2014-11-06 2020-01-21 Glycopeptide compositions

Country Status (30)

Country Link
US (7) US10188697B2 (en)
EP (4) EP4147710A1 (en)
JP (2) JP6797795B2 (en)
KR (2) KR102603756B1 (en)
CN (1) CN107073072B (en)
AU (1) AU2015341763B2 (en)
BR (1) BR112017009405B1 (en)
CA (1) CA2964524A1 (en)
CL (1) CL2017001139A1 (en)
CO (1) CO2017005391A2 (en)
CR (1) CR20170234A (en)
CY (2) CY1122960T1 (en)
DK (2) DK3215173T3 (en)
EA (1) EA035368B1 (en)
ES (2) ES2852550T3 (en)
HR (2) HRP20200101T1 (en)
HU (2) HUE049857T2 (en)
IL (1) IL252120B (en)
MX (1) MX2017005749A (en)
NZ (1) NZ731955A (en)
PH (1) PH12017500720A1 (en)
PL (2) PL3215173T3 (en)
PT (2) PT3215173T (en)
RS (2) RS59851B1 (en)
SA (1) SA517381446B1 (en)
SG (1) SG11201703568WA (en)
SI (2) SI3215173T1 (en)
TN (1) TN2017000182A1 (en)
WO (1) WO2016071495A1 (en)
ZA (1) ZA201702767B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731955A (en) * 2014-11-06 2023-07-28 Xellia Pharmaceuticals Aps Glycopeptide compositions
US20190000789A1 (en) * 2015-12-24 2019-01-03 Universiteit Leiden Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject
CN109069580A (en) * 2016-05-09 2018-12-21 埃克斯利亚制药有限公司 Stabilized glycopeptide antibiotic preparation
EP3544616A4 (en) * 2016-11-23 2020-12-09 Gufic Biosciences Limited Lyophilized pharmaceutical compositions of dalbavancin
JP7118412B2 (en) * 2017-07-31 2022-08-16 東洋製薬化成株式会社 Vancomycin Suspension Filled Capsule Formulation
CN109725101B (en) * 2017-10-31 2021-11-19 正大天晴药业集团股份有限公司 Method for detecting related substances in telavancin hydrochloride raw material
CN109078001B (en) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 Vancomycin nanoliposome composition and preparation method thereof
CA3132923A1 (en) 2019-03-08 2020-09-17 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
US20220133844A1 (en) * 2020-10-30 2022-05-05 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
WO2022234036A1 (en) * 2021-05-07 2022-11-10 Xellia Pharmaceuticals Aps Oral liquid vancomycin formulations
CN115804832A (en) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 Vancomycin aqueous solution composition
WO2023171588A1 (en) * 2022-03-08 2023-09-14 国立大学法人大阪大学 Plga preparation containing antimicrobial
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
MY128335A (en) 1994-01-28 2007-01-31 Lilly Co Eli Glycopeptide antibiotic derivatives
WO1997019690A1 (en) 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (en) 1997-09-02 1999-03-23 Kayaku:Kk Vancomycin injection
US6800608B2 (en) 2001-06-22 2004-10-05 Beckman Coulter, Inc. Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator
CA2478470A1 (en) * 2002-03-26 2003-10-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
JP2006506442A (en) 2002-07-09 2006-02-23 ポイント セラピューティクス， インコーポレイテッド Boroproline compound combination therapy
CN1802090A (en) * 2002-07-09 2006-07-12 尖端医疗有限公司 Boroproline compound combination therapy
US6900175B2 (en) 2002-11-18 2005-05-31 Vicuron Pharmaceuticals Inc. Methods of administering dalbavancin for treatment of bacterial infections
US7960337B2 (en) 2005-02-14 2011-06-14 Venues Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
CN1857716A (en) * 2006-03-14 2006-11-08 浙江大学 Vancomycin hydrochloride for injection and its preparing method
JP2008201778A (en) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd Vancomycin liquid preparation
CN102026666B (en) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 Formulation of insulinotropic peptide conjugates
JP2011080021A (en) 2009-10-09 2011-04-21 Bridgestone Corp Thermoplastic elastomer composition and molded product thereof
CA2981038C (en) * 2011-05-19 2018-09-25 Savara Inc. Dry powder vancomycin compositions and associated methods
WO2014026052A1 (en) 2012-08-08 2014-02-13 Vanderbilt University Composition with biofilm dispersal agents
RU2675859C2 (en) 2012-11-29 2018-12-25 Инсмед Инкорпорейтед Stabilised vancomycin formulations
CN104043104B (en) 2013-03-15 2018-07-10 浙江创新生物有限公司 The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin
US9616098B2 (en) * 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
CA2941867A1 (en) * 2014-03-14 2015-09-17 Cutispharma, Inc. Composition and method for vancomycin oral liquid
NZ731955A (en) * 2014-11-06 2023-07-28 Xellia Pharmaceuticals Aps Glycopeptide compositions
CN109069580A (en) 2016-05-09 2018-12-21 埃克斯利亚制药有限公司 Stabilized glycopeptide antibiotic preparation
US20220133844A1 (en) 2020-10-30 2022-05-05 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Also Published As

Publication number Publication date
PL3215173T3 (en) 2020-05-18
CA2964524A1 (en) 2016-05-12
JP2020183424A (en) 2020-11-12
EP3834837A1 (en) 2021-06-16
US10188697B2 (en) 2019-01-29
US20220354927A1 (en) 2022-11-10
HUE053347T2 (en) 2021-06-28
US11000567B2 (en) 2021-05-11
CO2017005391A2 (en) 2017-10-31
TN2017000182A1 (en) 2018-10-19
IL252120B (en) 2020-07-30
IL252120A0 (en) 2017-07-31
PH12017500720A1 (en) 2017-10-09
RS59851B1 (en) 2020-02-28
SA517381446B1 (en) 2020-09-21
RS61418B1 (en) 2021-03-31
CL2017001139A1 (en) 2017-12-01
KR20170078830A (en) 2017-07-07
SI3542812T1 (en) 2021-04-30
US20200069768A1 (en) 2020-03-05
US20210220433A1 (en) 2021-07-22
WO2016071495A1 (en) 2016-05-12
AU2015341763B2 (en) 2019-01-17
SG11201703568WA (en) 2017-05-30
EP3215173A1 (en) 2017-09-13
CY1124011T1 (en) 2022-05-27
PT3542812T (en) 2021-04-20
CR20170234A (en) 2018-01-15
US20230158101A1 (en) 2023-05-25
US11517609B2 (en) 2022-12-06
KR20230096142A (en) 2023-06-29
SI3215173T1 (en) 2020-03-31
AU2015341763A1 (en) 2017-06-08
BR112017009405B1 (en) 2024-02-06
US10039804B2 (en) 2018-08-07
EP3215173B1 (en) 2020-01-01
EP3542812B1 (en) 2021-01-13
EA035368B1 (en) 2020-06-03
ES2852550T3 (en) 2021-09-13
US11628200B2 (en) 2023-04-18
US20180133286A1 (en) 2018-05-17
US20190160142A1 (en) 2019-05-30
CY1122960T1 (en) 2021-10-29
EP4147710A1 (en) 2023-03-15
EP3542812A1 (en) 2019-09-25
KR102603756B1 (en) 2023-11-16
HRP20200101T1 (en) 2020-04-03
HUE049857T2 (en) 2020-10-28
DK3542812T3 (en) 2021-04-12
US10849956B2 (en) 2020-12-01
JP2017533218A (en) 2017-11-09
ZA201702767B (en) 2018-12-19
US20170348385A1 (en) 2017-12-07
MX2017005749A (en) 2018-01-11
EA201790997A1 (en) 2017-09-29
HRP20210342T1 (en) 2021-04-30
CN107073072B (en) 2021-06-18
ES2769849T3 (en) 2020-06-29
PT3215173T (en) 2020-04-03
EP3215173B8 (en) 2020-03-11
JP6797795B2 (en) 2020-12-09
NZ731955A (en) 2023-07-28
PL3542812T3 (en) 2021-07-12
CN107073072A (en) 2017-08-18
DK3215173T3 (en) 2020-03-23
BR112017009405A2 (en) 2018-01-02
JP7032488B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
HRP20210342T8 (en) Glycopeptide compositions
SG11201705415YA (en) Multi-supplement compositions
IL257131A (en) Compositions
HK1251559A1 (en) Plinabulin compositions
GB201501598D0 (en) Compositions
GB201515387D0 (en) Compositions
GB201515391D0 (en) Compositions
SI3349766T1 (en) Anti-hemorrhaging compositions
IL251479A0 (en) Compositions
GB201408167D0 (en) Compositions
GB201420306D0 (en) Compositions
GB2538335B (en) Compositions
PL3393503T3 (en) Compositions
GB201522892D0 (en) Compositions
GB201511469D0 (en) Compositions
GB201507673D0 (en) Compositions
GB201504995D0 (en) Compositions
GB201504045D0 (en) Compositions
GB201419849D0 (en) Compositions
GB201406863D0 (en) Compositions comprising variegin